Glutathione is a naturally occurring tripeptide (glutamate, cysteine, and glycine) that the body makes on its own. It is a dietary supplement and a research antioxidant, not an FDA-approved drug for the wellness uses described here. This page summarizes established biochemistry and areas of interest, not treatment claims.
The short answer
Glutathione's documented benefit is a modest, statistically detectable, and reversible reduction in skin pigmentation, produced by oral doses of 250–500 mg per day or by topical application. That is a narrower claim than the antioxidant, detox, and anti-aging marketing implies, and it comes with an inversion worth stating early: the evidence is strongest for the routes people are least often sold, and weakest for the intravenous drip.
The biochemistry, which is not in question
Glutathione is the principal intracellular antioxidant, cycling between reduced (GSH) and oxidized (GSSG) forms, with the ratio between them widely used as a marker of cellular oxidative state. It serves as cofactor for glutathione peroxidase, converting hydrogen peroxide and lipid peroxides into less reactive products, and it regenerates other antioxidants including vitamins C and E.
This part is textbook. The open question is not whether glutathione does these things inside cells — it does — but whether swallowing or injecting more of it changes anything measurable in a person whose synthesis is already intact. Intact oral absorption is limited, which is the stated rationale behind parenteral products.
Detoxification, and the one clinical use that is real
In the liver, glutathione participates in phase II conjugation, binding certain drugs, toxins, and metabolites to make them water-soluble for elimination. Its best-established clinical application sits here and is rarely the one being marketed: in acetaminophen overdose, treatment works by administering a precursor to replenish hepatic glutathione. That is a specific, emergency, precursor-based intervention — not a case for elective infusions in healthy people.
Glutathione status also influences lymphocyte function, which keeps immune effects a recurring research theme without yet producing controlled outcome data in healthy adults.
What the skin trials found
The most-cited human trial is a 12-week, three-arm randomized, double-blind, placebo-controlled study — 60 enrolled, 57 completing — comparing reduced glutathione (GSH) 250 mg/day, oxidized glutathione (GSSG) 250 mg/day, and placebo, published in Clinical, Cosmetic and Investigational Dermatology (Weschawalit et al., 2017; PMC5413479):
- Pigmentation — melanin index tended lower than placebo across sites, reaching statistical significance only in subgroup analysis (GSH, sun-exposed forearm, participants over 40, P=0.031).
- Wrinkles — GSH produced a significant reduction versus placebo at the sun-protected arm site (P=0.006).
- Elasticity — a tendency toward improvement in both glutathione arms, not statistically significant.
- Adverse events — 13.15% in the glutathione groups versus 21.05% on placebo.
The authors state the limitation directly: all participants were female, Asian, and within a defined age range, over a single 12-week window. The endpoints were instrument readings rather than outcomes a person would necessarily notice.
A 2025 systematic review in the International Journal of Dermatology (PMID 39444151) pooled a decade of this literature and reached a consistent picture: oral glutathione at 250–500 mg daily produced significant melanin-index reductions versus placebo; topical 0.5% outperformed 0.1% and placebo; combined oral plus topical beat either alone. It also describes the outcomes as moderately efficacious and unsustainable — benefits do not persist once treatment stops.
The route inversion
The same 2025 review examined intravenous glutathione, the form promoted most aggressively in cosmetic settings, and found a single placebo-controlled study behind it. Its conclusion is unusually blunt for a systematic review: "IV glutathione is contraindicated due to lack of efficacy and side effects."
This is not an isolated verdict. An earlier review in the Indian Journal of Dermatology, Venereology and Leprology (PMID 27088927) described intravenous glutathione as lacking efficacy evidence and noted it prompted regulatory warnings in the Philippines, finding only three randomized trials supporting topical and oral use. A Journal of Cosmetic Dermatology review of systemic skin-lightening agents (PMID 30133125) similarly cautioned against the IV route on adverse-event grounds while listing oral glutathione among promising systemic options.
Three independent dermatology reviews, converging on the same route, in the opposite direction from how it is sold.
What a glutathione claim has to clear
- Which route was tested? Oral, topical, and IV have separate evidence bases that do not transfer.
- How long was follow-up after dosing stopped? The reviewers' word for the effect is "unsustainable."
- Was the endpoint a colorimeter reading or something a participant reported? Almost all of it is the former.
- Who was studied? Mostly small, single-centre trials in narrow populations over 8–12 weeks.
In the United States glutathione is sold as a dietary supplement and is not an FDA-approved drug for antioxidant, anti-aging, or skin-lightening indications.